Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1996 Sep;61(3):259-64.
doi: 10.1136/jnnp.61.3.259.

Amantadine hydrochloride treatment in heredodegenerative ataxias: a double blind study

M I Botez  1 , T Botez-Marquard, R Elie, O L Pedraza, K Goyette, R Lalonde
Affiliations
Clinical Trial

Amantadine hydrochloride treatment in heredodegenerative ataxias: a double blind study

M I Botez et al. J Neurol Neurosurg Psychiatry. 1996 Sep.

Abstract

Objective: A group of 27 patients with Friedreich's ataxia and another group of 30 patients with olivopontocerebellar atrophies were each randomly divided into two subgroups, one receiving placebo and the other amantadine hydrochloride (AH; 200 mg daily) for three to four months.

Methods: The effect of double blind treatment was evaluated by simple visual and auditory reaction time (RT) and movement time (MT) for both right and left hands.

Results: The subgroup with olivopontocerebellar atrophies receiving AH showed significant improvement on seven out of eight variables studied by analysis of covariance. In patients with Friedreich's ataxia, improvement was definitely less. Treatment remained contraindicated for those with cardiomyopathies or drug intolerance.

Conclusion: The rationale of AH use in heredodegenerative ataxias can be explained by its replacement effect (dopamine release) and by direct involvement of N-methyl-D-aspartate (NMDA) in glutamate mediated neurotoxicity in cerebellar granular cells; memantine, an AH analogue, is a potent blocker of NMDA receptors.

PubMed Disclaimer

References

    1. J Neurol Neurosurg Psychiatry. 1988 Jul;51(7):914-9 - PubMed
    1. Pharmacopsychiatry. 1988 May;21(3):144-6 - PubMed
    1. Neurology. 1989 May;39(5):749-50 - PubMed
    1. Ital J Neurol Sci. 1989 Jun;10(3):291-300 - PubMed
    1. Clin Neuropharmacol. 1989 Aug;12(4):258-70 - PubMed

Publication types